The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative ...

Get any of our free daily email newsletters — news headlines, opinion, e-edition, obituaries and more. The National Cancer Institute, the federal research agency charged with leading the war against ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer, is studying ivermectin as a potential cancer treatment, according to ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation's second-largest killer, is studying ivermectin as a potential cancer treatment, according to ...

The National Cancer Institute is using federal funds to study whether cancer can be cured by ivermectin, a cheap, off-patent anti-parasitic and deworming drug that fringe medical groups falsely ...

The National Cancer Institute, the federal research agency charged with leading the war against the nation’s second-largest killer, is studying ivermectin as a potential cancer treatment, according to ...

Thirty-eight years ago, I was initiated into the oldest and one of the largest Black fraternities in the world: Alpha Phi Alpha Fraternity, Inc. It was one of the happiest days of my life. In ...

Since the pandemic began, Florida lawmakers and health officials have become fascinated with ivermectin for more than its approved human uses. Now, Florida’s Republican legislators want to make it ...

The Hastings brothers, from Lancashire in the north west of England, have now been given the all-clear Becca Longmire is a digital news writer-reporter at PEOPLE. She has been working at PEOPLE since ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...